Bibliografia

1. Sperandio V. Striking a balance: inter-kingdom cell-to-cell signaling, friendship or war? Trends Immunol 2004; 25(10): 505-7.
2. Tagg JR, Dierksen KP. Bacterial replacement therapy: adapting ’germ warfare’ to infection prevention. Trends Biotechnol 2003; 21: 217-23.
3. Di Pierro F, Adami T, Rapacioli G, Giardini N, Streitberger C. Clinical evaluation of the oral probiotic Streptococcus salivarius K12 in the prevention of recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes in adults. Expert Opin Biol Ther 2013; 13(3): 339-43.
4. Vera Fantinato V, Jorge AOC, Shimizu MT. Production of bacteriocin-like inhibitory substances (blis) by streptococcus salivarius strains isolated from the tongue and throat of children with and without sore throat. Revista de Microbiologia 1999; 30:332-4.
5. Tagg J, Wescomb P, Burton J. Oral streptococcal BLIS: Heterogeneity of the effector molecules and potential role in the prevention of streptococcal infections. International Congress Series 2006; 1289: 347-50.
6. Wescombe PA, Burton JP, Cadieux PA, et al. Megaplasmids encode differing combinations of lantibiotics in Streptococcus salivarius. Antonie Van Leeuwenhoek 2006; 90(3): 269-80.
7. Hyink O, Wescombe PA, Upton M, et al. Salivaricin A2 and the novel lantibiotic salivaricin B are encoded at adjacent loci on a 190-kilobase transmissible megaplasmid in the oral probiotic strain Streptococcus salivarius K12. Appl Environ Microbiol 2007; 73(4): 1107-13.
8. Jack RW, Tagg JR, Ray B. Bacteriocins of gram-positive bacteria. Microbiol Rev 1995; 59(2): 171-200.
9. Cosseau C, Devine DA, Dullaghan E, et al. The commensal Streptococcus salivarius K12 downregulates the innate immune responses of human epithelial cells and promotes host-microbe homeostasis. Infect Immun 2008; 76(9): 4163-75.
10. Power DA, Burton JP, Chilcott CN, Dawes PJ, Tagg JR. Preliminary investigations of the colonisation of upper respiratory tract tissues of infants using a paediatric formulation of the oral probiotic Streptococcus salivarius K12. Eur J Clin Microbiol Infect Dis 2008; 27(12): 1261-3.
11. Horz HP, Meinelt A, Houben B, Conrads G. Distribution and persistence of probiotic Streptococcus salivarius K12 in the human oral cavity as determined by real-time quantitative polymerase chain reaction. Oral Microbiol Immunol 2007; 22(2): 126-30.
12. JP Burton, CN Chilcott, JR Tagg. The rationale and potential for the reduction of oral malodour using Streptococcus salivarius probiotics. Oral Diseases(2005; 11 (Suppl. 1): 29-31.
13. Burton JP, Chilcott CN, Moore CJ, Speiser G, Tagg JR. A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. J Appl Microbiol 2006; 100(4): 754-64.
14. Tagg JR. Prevention of streptococcal pharyngitis by anti-Streptococcus pyogenes bacteriocin-like inhibitory substances (BLIS) produced by Streptococcus salivarius. Indian J Med Res. 2004 May;119 Suppl:13-6.
15. Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med 2012; 5: 991-7.
16. Di Pierro F, Colombo M, Zanvit A, Risso P, Rottoli AS. Use of Streptococcus salivarius K12 in the prevention of streptococcal and viral pharyngotonsillitis in children. Drug Healthc Patient Saf 2014; 6: 15-20.
17. Burton J, Wescombe PA, Moore CJ, Chilcott CN, Tagg JR. Safety assessment of the oral cavity probiotic Streptococcus salivarius K12. Appl Environ Microbiol 2006; 72(4): 3050-3.
18. Burton JP, Chilcott CN, Wescombe PA, Tagg JR. Extended Safety Data for the Oral Cavity Probiotic Streptococcus salivarius K12. Probiotics Antimicrob Proteins 2010; 2 (3): 135-44.
19. Burton JP, Cowley S, Simon RR, et al. Evaluation of safety and human tolerance of the oral probiotic Streptococcus salivarius K12: a randomized, placebo-controlled, double-blind study. Food Chem Toxicol 2011; 49(9): 2356-64.